Home > Faculty > Faculty Web Pages





 

Mark Schneiderhan, Ph.D.
Assistant Professor of Pharmacy
Phone: (312)
413-4513
E-mail: Markedw@uic.edu

 

Overview of Clinical Responsibilities

The clinical services are consultative in nature providing formal and informal consultation to the psychiatric staff including psychiatrist attendings and residents. This includes monitoring and adjusting of medications, education, referrals, and treatment planning. He provides direct consultation for Tuesday afternoons (Dr. Klamen and Dr. Doves) clinics and Thursday morning clinic with Dr. Krasuski. Provide psychopharmacology lectures during the supervision rounds, provide assessment of extra-pyramidal side effects (EPS) utilizing the AIMS or Discus rating scales. Provide written psychopharmacology recommendations to the attending psychiatrist. He is also available for additional consultative support to the psychiatrist including: Computer searches of past hospitalizations, medications and laboratory reports if indicated by the patient. A copy of the data will be included in the patient’s records to be reviewed by the psychiatrist. Obtain a base-line blood pressure, heart rate, and body weight when appropriate. Administer haloperidol or fluphenazine decanoate IM injections when treatment is ordered. Also, he can be called to administer and assess clinical rating instruments such as the Beck’s Depression Inventory or Geriatrics Depression Scale and provide a basic neuro-psychiatric mental status testing. In addition, he can provide Clozapine monitoring services: Benefits of service include: - 1) The availability of consultative support in initiating clozapine and monitoring patients (i.e. WBC, Abnormal Involuntary Movements, Drug interactions, Adverse side-effects). 2) Developing guidelines for the prescribing and monitoring of Clozapine in the ambulatory setting.

He also an investigator and research coordinator for out-patient studies (see below). The responsibilities are to assist and supervise subject recruitment and consent to participate in research, management of the study records, storage, accountability, and dispensing of study medications, and tracking subject study timetables. He also provides clinical monitoring of patients in the clinical studies. Has received training at UIC to administer the following clinical rating scales: Mongomery Asbury Depression Scale, Hamiltion Depression Rating Scale and the Brief Psychiatric Rating Scales.

He provides services to the Partial Hospital Program which includes a pharmacist facilitated medication education group once a week and weekly staff meetings. The Medication Education Group is a unique learning environment for pharmacy and medical students on psychiatry rotation. Patients included in the group are patients who are clinically stable on current medication prescribed by the attending psychiatrist. The attending psychiatrist will be notified if the patient’s symptoms are acute and require further interventions beyond the services of the Medication Education Group. The education groups discuss a wide variety of topics including common medication side-effects, common psychiatric symptoms, compliance issues, drug and food interactions, time to treatment response, and duration of treatment. Patients are introduced to the staff and each other prior to starting the group. If some patients are new to the group the facilitator will usually ask for a volunteer from the group to explain the purpose of the group. The facilitator will facilitate group discussion about medications. To facilitate discussion, the facilitator may review an individual patient’s medications, determine if other patients are on similar medications and then facilitate a discussion focused on the medication class and characteristics common with the medications. The group forum allows the pharmacist to assess the patients may require the pharmacist to contact the attending psychiatrist to discuss problems and recommendations to the attending psychiatrist. Then the pharmacist documents and discusses pertinent information with the attending psychiatrist.

Provides psychopharmacological education to the pharmacy, medical, nursing, social work, and psychology trainees and staff.

Specialty Certification

DATE

1997 – 2001

CERTIFICATE

Board Certified Psychiatric Pharmacist (BCPP)

Professional Education

DATE

INSTITUTION

DEGREE

1990 – 1992

University of Kentucky, College of Pharmacy, Lexington, Kentucky

Doctor of Pharmacy

1981 – 1986

Ferris State University, College of Pharmacy, Big Rapids, Michigan

Bachelor of Science in Pharmacy

Post-Doctoral Training

DATE

INSTITUTION

CERTIFICATE

1993 – 1994

Western Missouri Mental Health Center

Kansas City, Missouri

Fellowship in Psychiatric Pharmacotherapy

1992 – 1993

Western Missouri Mental Health Center Kansas City, Missouri

ASHP Accredited Residency in Psychiatric Pharmacotherapy

Academic Appointments

DATE

INSTITUTION

POSITION

1995 – Present

University of Illinois at Chicago Chicago, Illinois

Assistant Clinical Professor, Calendar year appointment

1994 - 1995

University of Kentucky Lexington, Kentucky

Assistant Clinical Professor, Calendar year appointment

1992 - 1994

University of Missouri-Kansas City Kansas City, Missouri

Clinical Instructor

Hospital Appointments

DATE

INSTITUTION

POSITION

1999 – Present

University of Illinois Medical Center Department of Pharmacy Practice Chicago, Illinois

Pharmacotherapist in Ambulatory Care Psychiatry

1995 - 1999

Michael Reese Hospital and Medical Center Departments of Pharmacy and Psychiatry Chicago, Illinois

Pharmacotherapist in Psychiatry

1994 - 1995

Appalachian Regional Healthcare Psychiatric Center, Hazard, Kentucky

Psychopharmacy Specialist

1992 – 1994

Veterans Administration, Kansas City, Missouri

I.V. Pharmacist, part-time

1991 – 1992

Good Samaritan Hospital, Lexington, Kentucky

Staff Pharmacist, part-time

1986 – 1990

United States Public Health Service (USPHS) Indian Health Service (IHS) Chinle, Arizona

Senior Assistant Pharmacist; Temporary Chief Pharmacist, Kayenta, Arizona.

Honors

  • The Rho Chi Honor Society, April 12th, 2000
  • Scholarship Award, Bristol-Myers Squibb U.S. Pharmaceutical Division, 1993
  • Promotion, Lieutenant, E-3, Senior Assistant Pharmacist, 1989
  • USPHS Isolative Hardship Award, 1987

Professional Activity

  • Member, American Society of Health-System Pharmacists 1986 - 2000
  • Member, American Pharmaceutical Association 1986 - 2000
  • Member, Illinois Chapter of the Society of Health-System Pharmacists 1997 - 2000

Publications:

Under Peer-review:

  • Schneiderhan, ME, Kaplan KJ. Autonomy, Gender and Preference for Paternalistic or Informative Physicians: A Study of the Doctor-Patient Relations. JAMA, 2000 (submitted).
  • Kaplan KJ, Harrow M, Schneiderhan ME. Patient Gender, Doctor Involvement, and decisions on Dying. Lancet, 2000 (submitted).
Peer-reviewed Published:
  • Schneiderhan ME. Physician-Assisted Suicide and Euthanasia: The Pharmacist’s Perspective. In: Kaplan KJ. ed. Right to Die versus Sacredness of Life. Baywood Publishing Co. Inc. Amityville, NY. and Omega, 2000;40(1):89-99.
  • Kaplan KJ, Lachenmeier F, Harrow M, O’Dell J, Uziel O, Schneiderhan ME, Cheyfitz K. Psychosocial versus Biomedical Risk Factors in Kevorkian’s first 47 Physician-Assisted Deaths. In: Kaplan KJ. ed. Right to Die versus Sacredness of Life. Baywood Publishing Co. Inc. Amityville, NY. and Omega, 2000;40(1):109-163.
  • Marken PA, Schneiderhan ME. Assessment of Psychiatric Illness. In: DiPiro, Talbert, Hayes, Yee, Matzke, Posey. eds. Pharmacotherapy: A Pathophysiological Approach, Fourth Edition. 1999;58:1039-1055.
  • Bunker MT, Marken PA, Schneiderhan ME, Ruehter VL. Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. J Child Adolesc Psychopharmacol 1997;7(1):65-69.
  • Littrell RA, Schneiderhan M, The Neurobiology of Schizophrenia. Pharmacotherapy 1996;16(6):143s-147s; discussion 166s-168s.
  • Marken PA, Schneiderhan ME. Assessment of Psychiatric Illness. In: DiPiro, Talbert, Hayes, Yee, Matzke, Posey. eds. Pharmacotherapy: A Pathophysiological Approach, Third Edition. 1996;61:1293-1300.
  • Schneiderhan ME, Marken PA. An atypical course of neuroleptic malignant syndrome. J Clin Pharmacol. 1994;34(4):325-334.
  • Schneiderhan ME. Is vitamin E effective in the treatment of tardive dyskinesia. Ann Pharmacother. 1993;27(3):311-312.

Peer-reviewed: In Preparation:

  • Schneiderhan ME. Refining Practice with Outcomes Data. Unit 4. UK Prime Care Disease State Management Module. University of Kentucky Office of Continuing Pharmacy Education, 2000.
  • Schneiderhan ME, Littrell RA. The Pharmacist’s Role in Caring for the Patient with Depression. Unit 3. UK Prime Care Disease State Management Module. University of Kentucky Office of Continuing Pharmacy Education, 2000.
  • Marken PA, Schneiderhan ME. Assessment of Psychiatric Illness. In: DiPiro, Talbert, Hayes, Yee, Matzke, Posey. eds. Pharmacotherapy: A Pathophysiological Approach, Fifth Edition. 2000.

Letter:

  • Schneiderhan ME, Gross AG, Marken PA; Ruehter VL, Schmidt SL. Conversion from oral to i.m. fluphenazine not a simple matter. Am J Health Syst Pharm 1995 Dec 15:52(24):2826-7.

Abstracts:

  • Kaplan KJ, Harrow M, Schneiderhan ME. Patient Gender, Doctor Involvement, and Decisions on Dying. The One Hundered and Fifty-Third Annual Meeting of the American Psychiatric Association. May 13-18th. 2000;15C:62.
  • Schneiderhan ME, Gross AC, Kendall MM, Schmidt SL, Renno VL, Marken PA. A Drug Utilization Evaluation of Fluphenazine Decanoate Conversion in a State Psychiatric Hospital. ASHP Midyear Clinical Meeting 29:P-456(E) (Dec) 1994. (IPA #3111872)
  • Jaggers M, Schneiderhan M, et al. Absence of antimicrobial resistance with restricted use of nalidixic acid for shigellosis. USPHS Professional Association, Abstract, 25th Annual Meeting, June 3 - 6, 1990.

Research Projects

Funded Grants/Sponsorships:

  • Clinician-Patient Relationship Preferences Among Male and Female Psychiatric Patients. Sponsored by Research Infrastructure Support Program (RISP), Co-investigator Awarded $8000.00.

  • The Assessment of Nizatidine for the Prevention of Olanzapine-Associated weight gain in patients with Schzophrenia. Sponsored by Lilly Research. Co-coordinator, April, 2000. IRB approved

  • A Development Model of Doctor-Patient Relations. Kaplan K., Schneiderhan ME. The 1999 Summer Student Research Fellowship Program. Sponsored by the Research and Education Foundation of the Michael Reese Medical Staff. $1,800; June 1999.

  • A Development Model of Doctor-Patient Relations. Kaplan K., Schneiderhan ME. The 1998 Summer Student Research Fellowship Program. Sponsored by the Research and Education Foundation of the Michael Reese Medical Staff. $1,800; June 1998.
  • A Development Model of Doctor-Patient Relations. Kaplan K., Schneiderhan ME. The 1997 Summer Student Research Fellowship Program. Sponsored by the Research and Education Foundation of the Michael Reese Medical Staff. $1,800; June 1997.
  • A Retrospective Comparison of Valproic Acid and Lithium in Patients with Manic Symptoms. Abbott Pharmaceuticals Inc. Approved and funded; $5000; September, 1993.
  • Fluphenazine Decanoate Drug Use Evaluation. UpJohn. Approved and funded; $1000; October, 1993.

Unfunded Grants:

  • A Randomized, Blinded, Comparison of Clinical and Economic outcomes in a Bipolar Disorder Critical Pathway Model Versus a Traditional Clinical Model. Seabolt J., Schneiderhan, ME. Submitted to Abbott Laboratories; March 16, 1998.

  • A Randomized, Blinded, Comparison of Clinical and Economic outcomes in a Major Depression Critical Pathway Model Versus a Traditional Clinical Model. Seabolt J., Schneiderhan, ME. Submitted to 1998 NARSAD Young Investigator Award and HansVahlteich Endowment Program Funds.

  • Pharmacist Perspective of Physician Assisted Death in Michigan, Illinois, and Oregon: An Empirical Study. Schneiderhan ME. 1998 HansVahlteich Endowment Program Funds.

  • A Comparison of Antidepressant Treatment Outcome and Utilization of Psychiatric Services in HIV-infected Patients versus Non-HIV-Infected Patients with Major Depression. Submitted to the Michael Reese Research Foundation.

Speaking Engagements

  • Kaplan KJ, Harrow M, Schneiderhan ME. "Patient Gender, Doctor Involvement, and Decisions on Dying." Symposium 15: Doctor influence on Hastened Death in Women and Men Worldwide. The One Hundered and Fifty-Third Annual Meeting of the American Psychiatric Association. Chicago, May 15th. 2000.
  • Schneiderhan ME. "Pharmaceutical Care of the Adolescent Depressed Patient." Presented at UIC sponsored Drug Management of Childhood and Adolescent Depression and Suicide. Oak Brook, April 7th, 2000.

up.gif (93 bytes)

©2001 Department of Psychiatry
UIC 912 S. Wood Street
Chicago , IL - 60612, USA
Phone: 1-312-996-7206
webmaster@psych.uic.edu